Centre Asset Management LLC Takes $9.34 Million Position in Jazz Pharmaceuticals plc (NASDAQ:JAZZ)

Centre Asset Management LLC purchased a new position in shares of Jazz Pharmaceuticals plc (NASDAQ:JAZZ - Free Report) during the fourth quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor purchased 75,803 shares of the specialty pharmaceutical company's stock, valued at approximately $9,335,000. Jazz Pharmaceuticals makes up about 2.1% of Centre Asset Management LLC's investment portfolio, making the stock its 21st largest position. Centre Asset Management LLC owned 0.13% of Jazz Pharmaceuticals at the end of the most recent quarter.

Several other institutional investors and hedge funds have also recently added to or reduced their stakes in JAZZ. EverSource Wealth Advisors LLC grew its holdings in shares of Jazz Pharmaceuticals by 55.1% during the second quarter. EverSource Wealth Advisors LLC now owns 273 shares of the specialty pharmaceutical company's stock valued at $30,000 after buying an additional 97 shares during the last quarter. GAMMA Investing LLC grew its stake in Jazz Pharmaceuticals by 41.3% during the 3rd quarter. GAMMA Investing LLC now owns 414 shares of the specialty pharmaceutical company's stock valued at $46,000 after purchasing an additional 121 shares during the last quarter. Arizona State Retirement System increased its holdings in shares of Jazz Pharmaceuticals by 0.8% in the second quarter. Arizona State Retirement System now owns 16,580 shares of the specialty pharmaceutical company's stock valued at $1,770,000 after purchasing an additional 130 shares during the period. Coldstream Capital Management Inc. lifted its holdings in shares of Jazz Pharmaceuticals by 7.7% during the third quarter. Coldstream Capital Management Inc. now owns 2,300 shares of the specialty pharmaceutical company's stock worth $259,000 after purchasing an additional 165 shares during the period. Finally, Itau Unibanco Holding S.A. boosted its position in Jazz Pharmaceuticals by 63.2% in the third quarter. Itau Unibanco Holding S.A. now owns 444 shares of the specialty pharmaceutical company's stock valued at $49,000 after buying an additional 172 shares during the last quarter. 89.14% of the stock is currently owned by hedge funds and other institutional investors.

Jazz Pharmaceuticals Price Performance

Shares of JAZZ stock traded down $3.20 on Friday, reaching $120.56. 683,587 shares of the company were exchanged, compared to its average volume of 556,644. Jazz Pharmaceuticals plc has a 1 year low of $99.06 and a 1 year high of $134.17. The company has a debt-to-equity ratio of 1.46, a quick ratio of 3.74 and a current ratio of 4.26. The business has a 50-day moving average price of $121.03 and a 200 day moving average price of $113.68. The company has a market cap of $7.29 billion, a price-to-earnings ratio of 16.98, a P/E/G ratio of 1.04 and a beta of 0.56.

Analysts Set New Price Targets

Several research firms have recently commented on JAZZ. Robert W. Baird upped their price objective on shares of Jazz Pharmaceuticals from $154.00 to $162.00 and gave the company an "outperform" rating in a report on Monday, November 18th. Needham & Company LLC reiterated a "buy" rating and set a $207.00 price objective on shares of Jazz Pharmaceuticals in a research note on Thursday, December 12th. Royal Bank of Canada reissued an "outperform" rating and issued a $179.00 price objective on shares of Jazz Pharmaceuticals in a report on Tuesday, December 10th. Morgan Stanley upgraded Jazz Pharmaceuticals from an "equal weight" rating to an "overweight" rating and lifted their price target for the company from $140.00 to $175.00 in a research report on Thursday, December 12th. Finally, HC Wainwright restated a "buy" rating and issued a $200.00 price objective on shares of Jazz Pharmaceuticals in a research report on Friday, November 22nd. Two analysts have rated the stock with a hold rating, thirteen have given a buy rating and one has issued a strong buy rating to the company's stock. According to MarketBeat.com, the company currently has an average rating of "Moderate Buy" and a consensus price target of $177.00.

Insiders Place Their Bets

In other news, CEO Bruce C. Cozadd sold 1,000 shares of the firm's stock in a transaction dated Friday, November 1st. The shares were sold at an average price of $110.84, for a total value of $110,840.00. Following the transaction, the chief executive officer now directly owns 428,976 shares of the company's stock, valued at approximately $47,547,699.84. This trade represents a 0.23 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at this link. Also, EVP Neena M. Patil sold 3,700 shares of the stock in a transaction dated Friday, November 8th. The shares were sold at an average price of $123.41, for a total transaction of $456,617.00. Following the completion of the sale, the executive vice president now owns 33,048 shares of the company's stock, valued at approximately $4,078,453.68. The trade was a 10.07 % decrease in their position. The disclosure for this sale can be found here. In the last three months, insiders sold 6,753 shares of company stock worth $816,289. Corporate insiders own 4.20% of the company's stock.

Jazz Pharmaceuticals Company Profile

Jazz Pharmaceuticals plc identifies, develops, and commercializes pharmaceutical products for unmet medical needs in the United States, Europe, and internationally. The company offers Xywav for cataplexy or excessive daytime sleepiness (EDS) with narcolepsy and idiopathic hypersomnia; Xyrem to treat cataplexy or EDS with narcolepsy; Epidiolex for seizures associated with Lennox-Gastaut and Dravet syndromes, or tuberous sclerosis complex; Zepzelca to treat metastatic small cell lung cancer, or with disease progression on or after platinum-based chemotherapy; Rylaze for acute lymphoblastic leukemia or lymphoblastic lymphoma; Enrylaze to treat acute lymphoblastic leukemia and lymphoblastic lymphoma; Defitelio to treat severe hepatic veno-occlusive disease; and Vyxeos for newly-diagnosed therapy-related acute myeloid leukemia.